Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.
Ever since the introduction of anti-tumor necrosis factor (TNF) agents, concerns have been raised regarding their potential for developing malignancy. We report the development of thymic atypical carcinoid tumor 9 months after the initiation of etanercept therapy in a patient having refractory spondylarthritis. This case indicates the need for following large cohorts of patients receiving anti-TNF agents to address the long-term effect of these agents on malignancies.
Simsek
Ismail
I
Division of Rheumatology, Department of Medicine, Gülhane Military School of Medicine, Etlik/Ankara, 06018, Turkey. isimsek@gata.edu.tr
Pay
Salih
S
Dinc
Ayhan
A
Erdem
Hakan
H
Kurt
Bulent
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D002276:Carcinoid Tumor / Q000139:chemically induced*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D047748:Pituitary ACTH Hypersecretion / Q000209:etiology; D018124:Receptors, Tumor Necrosis Factor; D025241:Spondylarthritis / Q000188:drug therapy; D013953:Thymus Neoplasms / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept